Blocking the interaction between TGF-β and LTBP1 can impede the activity of natural killer/T cells by deactivating the TGF-β/Smad and p38MAPK signaling pathways, consequently impacting the advancement of lymphoma [37]. This evidence concerns the gene TGFB1 and lymphoma.